Stocks and Investing Stocks and Investing
Thu, January 20, 2022

Evan Seigerman Upgraded (VRTX) to Buy and Increased Target to $274 on, Jan 20th, 2022


Published on 2024-10-27 19:21:23 - WOPRAI, Evan Seigerman
  Print publication without navigation


Evan Seigerman of BMO Capital, Upgraded "Vertex Pharmaceuticals Incorporated" (VRTX) to Buy and Increased Target from $202 to $274 on, Jan 20th, 2022.

Evan has made no other calls on VRTX in the last 4 months.



There are 8 other peers that have a rating on VRTX. Out of the 8 peers that are also analyzing VRTX, 1 agrees with Evan's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Do Kim of "Piper Sandler" Downgraded from Buy to Hold and Decreased Target to $218 on, Friday, November 19th, 2021


These are the ratings of the 7 analyists that currently disagree with Evan


  • Liisa Bayko of "Evercore ISI Group" Maintained at Buy and Held Target at $265 on, Wednesday, December 22nd, 2021
  • Mohit Bansal of "Wells Fargo" Initiated at Buy and Held Target at $270 on, Thursday, December 9th, 2021
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy and Held Target at $275 on, Thursday, December 2nd, 2021
  • Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $265 on, Thursday, December 2nd, 2021
  • Brian Skorney of "Baird" Maintained at Buy and Held Target at $240 on, Thursday, December 2nd, 2021
  • Debjit Chattopadhyay of "Guggenheim" Maintained at Strong Buy with Increased Target to $286 on, Wednesday, December 1st, 2021
  • Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Increased Target to $341 on, Wednesday, December 1st, 2021

Contributing Sources